Format

Send to

Choose Destination
J Med Screen. 2012 Mar;19(1):51-4. doi: 10.1258/jms.2012.011085. Epub 2012 Feb 22.

The value of early second trimester PAPP-A and ADAM12 in screening for pre-eclampsia.

Author information

1
Wolfson Institute of Preventive Medicine, Barts and London School of Medicine and Dentistry, Queen Mary University of London, Charterhouse Square, London EC1M 6BQ. j.p.bestwick@qmul.ac.uk

Abstract

OBJECTIVE:

To estimate the pre-eclampsia screening performance of PAPP-A (pregnancy-associated plasma protein-A) and ADAM12 (A Disintegrin And Metalloprotease 12) in the early second trimester of pregnancy.

METHODS:

Stored frozen serum samples from a previously published nested case-control study comprising 77 women who developed pre-eclampsia and 224 unaffected controls were thawed and assayed for PAPP-A and ADAM12. Levels were converted into multiple of the unaffected median (MoM) values.

RESULTS:

Neither PAPP-A or ADAM12 were significantly different in women who developed pre-eclamspia compared with unaffected controls (PAPP-A: 0.97 MoM [95% confidence interval 0.73 to 1.25], ADAM12: 1.01 MoM [0.91 to 1.13]).

CONCLUSION:

Our results do not support the use of PAPP-A or ADAM12 in early second trimester antenatal screening for pre-eclampsia.

PMID:
22357350
DOI:
10.1258/jms.2012.011085
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Atypon
Loading ...
Support Center